Change Tracker · Health, Life Sciences and Care Systems · 11 September 2026

Ebola spreads to 60 health zones as pathogen access goes bilateral

The Bundibugyo epidemic has reached 60 health zones across six provinces at a 48.1 per cent case fatality ratio, US measles has reached 3,134 confirmed cases, and three African states have refused US bilateral demands for pathogen access.

Edition 4. Previous cycle: “Ebola response trails transmission while US immunisation cover keeps thinning” (August 2026).

Last cycle read communicable disease as this topic's binding constraint. It still is, and the numbers have moved: WHO records 5794 confirmed Bundibugyo cases and 2786 deaths across 60 health zones as of 26 August (World Health Organization, August 2026), and US measles stands at 3,134 confirmed cases against 2,289 in all of 2025 (CDC, September 2026). The new movement is elsewhere. Global health financing retrenchment, Stable last cycle, now reads Accelerating after Germany's draft budget cut the flexible fund for international public health and the United States proposed ending its PAHO contribution. Alongside it a signal enters the register for the first time: pathogen access is being traded bilaterally while the multilateral annex stays unfinished. What a country's samples are now worth is the question to hold.

Trend Radar

The momentum register mapped onto the horizon: ring = when a trend bites, sector = the cycle's pattern cluster, blip size = heat, arrows = momentum, dashed ghosts and tails = drift since the prior cycle. Hover any blip for its full entry; expand for the reading view.

Momentum this cycle 6 Accelerating 3 Stable 1 Fading · 1 new to the register · 2 warmed a direction · 1 cooled a direction · 1 left the register
⤢ Expand

Momentum across the topic

TrendClusterHorizonHeatMomentumEvidence

Ring = when the trend bites (Now, Next, Later), sector = pattern cluster, blip size and stroke = heat (impact × likelihood), arrows = momentum direction this cycle. Wild cards sit on the dashed outer rim. Drift tails show movement against the prior cycle's register: a dashed ghost is the trend’s previous state and the dotted tail leads to where it sits now; a grey crossed ghost marks a trend carried last cycle but absent from this one. Trends with no tail held their grades.

Pattern narrative

Cover thins while outbreaks widenEvolving Risk

The sources put this cycle's deficit in the same place: what is left to detect and prevent with. WHO ties onward household and facility transmission to delays in recognising cases (World Health Organization, August 2026), and its 24 August recommendations ask for road checkpoints, postponed gatherings and surveillance on the river routes into Kinshasa (World Health Organization, August 2026). CDC puts recurring US outbreaks down to kindergarten measles coverage at 92.4 per cent, against the 95 per cent at which community immunity holds (CDC, September 2026); globally, 13.5 million children missed a first DTP dose in 2025 (Johns Hopkins IVAC, July 2026). The money behind response is moving the same way. Germany cuts its flexible international health fund by 15.3 per cent while defence spending rises (Health Policy Watch, August 2026), and the US budget request proposes ending PAHO funding at a body already cutting 17 per cent (Health Policy Watch, September 2026). Vaccine policy is the outlier: 30 states including DC have already decoupled, and the courts blocked the earlier federal schedule (KFF, August 2026).

Access settled by bargain, not by ruleTransformation Driver

Two very different goods are now being settled the same way. Twenty-six manufacturers hold most-favoured-nation agreements covering 89 per cent of the branded drug market after nine more signed on 31 August (The White House, August 2026), which makes the 29 September tariff tranche less a deadline than a reserve price (Office of the Federal Register, April 2026). The same logic has reached pathogens. Namibia, Zimbabwe and Ghana have refused US bilateral demands for data and pathogen access that carry no benefit-sharing guarantee, while the Kenya and DRC agreements face legal challenge (Health Policy Watch, September 2026). The multilateral alternative is not finished: July's negotiating round closed with the contractual arrangements and the definition of benefits still open (World Health Organization, July 2026), and Europe's procurement route has not moved since May (Council of the European Union, May 2026).

Delivery now, durability laterEmerging Opportunity

Both access signals are delivering on terms that expire. Medicare's GLP-1 Bridge has delivered savings to over 500,000 seniors in two months (The White House, August 2026), at a $245 net monthly price and on demonstration authority running to the end of 2027 after the permanent model was shelved (KFF, May 2026). England's Fair Pay Agreement has its negotiating body due this year and its first £500 million in 2028-29 (Department of Health and Social Care, July 2026). On discovery, the pipeline still has breadth without a verdict: mid-stage and late-stage efficacy trials are what will settle it (BioPharma Dive, July 2026).

Signals gaining momentum

  1. Bundibugyo Ebola emergency. A confirmed chain on the river route into Kinshasa would turn a provincial emergency into a border and procurement question within days.
  2. Global health financing retrenchment. Germany's 2027 budget is still in draft and the US appropriation is still live; both decide what outbreak response is funded with next year.
  3. Pathogen access as bilateral leverage. If the September negotiating round closes without contractual text, bilateral terms become the working standard by default.
  4. US measles elimination at risk. The November review is the forcing event, and losing status makes outbreak response a recurring state budget line.

Wild Cards to Watch

Bundibugyo transmission establishes in Kinshasa

Disruptive RiskPotential impact: Very High

Surprise characteristics: Sustained transmission reaches a major urban centre on the river network, in an epidemic caused by a species with no licensed vaccine or approved treatment.

Early warning indicators: Confirmed cases in Tshopo spreading downstream; contact follow-up falling below current levels; new health zones along waterway corridors.

WHO's 24 August recommendations already ask the Democratic Republic of the Congo to put surveillance on vessels running to Kinshasa (World Health Organization, August 2026). That instruction is the tell: the route is being treated as live.

Bilateral pathogen deals become the working standard

Disruptive RiskPotential impact: Very High

Surprise characteristics: The multilateral annex stalls, and pathogen-access terms are set instead by bilateral agreements attached to bilateral funding.

Early warning indicators: The September round closing without contractual text; further states signing or refusing US terms; rulings in the Kenya and DRC challenges.

Three African states have already refused the terms and two signed agreements are in court (Health Policy Watch, September 2026), while the multilateral text still has its contractual arrangements open (World Health Organization, July 2026). Taken together, the sources suggest the default is drifting toward whoever pays.

Ervebo shows cross-protection against Bundibugyo

Disruptive OpportunityPotential impact: High

Surprise characteristics: A vaccine licensed against a different Ebola species turns out to protect in the middle of an epidemic it was never designed for.

Early warning indicators: Early signals from the clinical trial running alongside health-worker vaccination; updated WHO vaccine prioritisation advice.

Health-worker vaccination with Ervebo began in Kisangani on 27 August alongside a trial, and WHO is explicit that protection against Bundibugyo in humans is not known (World Health Organization, August 2026). A clean result would move the response from containment toward interruption.

Implications

Three dated decisions sit inside the next three weeks. The eighth negotiating round on pathogen access runs from 14 to 18 September, and whether it produces contractual text is what decides if the bilateral route becomes the default (World Health Organization, July 2026). The UN High-Level Meeting on 25 September will consider a declaration modified since it went under the silence procedure in July, with its review timeline shortened to three years and the financing campaigners cite still uncommitted (Health Policy Watch, August 2026). Then 29 September brings the second tariff tranche for manufacturers outside Annex III (Office of the Federal Register, April 2026): after 26 pricing agreements, the live question for anyone holding patented-product supply is the price of exemption rather than the duty itself.

Bibliography

Source tiers: Tier 1, governments, regulators and intergovernmental bodies. Tier 2, think-tanks, academic institutes, major consultancies and quality data providers. Tier 3, quality journalism and specialist trade press. Tier 4, vendor, company and practitioner sources, used only as directional corroboration.

This Change Tracker is one component of a Shaping Tomorrow intelligence cycle on Health, Life Sciences and Care Systems. Every monitored topic also includes weekly Signal Scans on emerging developments and weak signals, and a quarterly Decision Intelligence briefing that converts the cycle into board-level strategic implications. Cycles may also close with Action Triggers, an end-of-cycle synthesis that reads across the three formats and surfaces patterns no single deliverable carries on its own. Continuous intelligence on this topic is available as a Single-Topic or Multi-Topic programme.

Discuss a Tailored Programme

Prepared by Shaping Tomorrow: 11 September 2026